Pamela Hardwick

University of Alabama at Birmingham — United States

Medicine · Health Sciences

6h-index489citations15works1.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(11), Protein Degradation and Inhibitors(6), Chronic Lymphocytic Leukemia Research(4), HIV/AIDS drug development and treatment(2), Chronic Myeloid Leukemia Treatments(2)

Publications15 total

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy
Blood·2024· 3 cited
Combination Regimens in MM Post Autologous Hematopoietic Cell Transplantation (AHCT) to Eliminate MRD Utilizing Iberdomide (COMMANDER): Results of Dose-Finding Component of a Phase 1b/2 Trial
Blood·2024· 2 citedOpen Access
P-326 Phase 1b/2 Trial of Iberdomide in Combination With Daratumumab, Dexamethasone +/-Carfilzomib To Eliminate MRD After Induction Therapy and ASCT in NDMM
Clinical Lymphoma Myeloma & Leukemia·2024
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
The Lancet Haematology·2023· 134 citedOpen Access
Interim Analysis of Investigator-Initiated Phase 2 Trial of Siltuximab in Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR T-Cell Therapy
Transplantation and Cellular Therapy·2023· 7 cited
Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial
Blood·2022· 1 cited
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy
American Journal of Hematology·2022· 10 cited
Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy
Transplantation and Cellular Therapy·2022
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Journal of Clinical Oncology·2021· 240 cited
Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy
Blood·2021· 2 cited
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial
Blood·2021· 8 cited
OAB-051: Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM)
Clinical Lymphoma Myeloma & Leukemia·2021· 1 cited
A phase II trial of regorafenib for advanced urothelial cancer (aUC) following prior chemotherapy.
Journal of Clinical Oncology·2020· 1 cited
Impact of Autologous Hematopoetic Stem Cell Transplant (AHCT) on Measurable Residual Disease (MRD) By Next Generation Sequencing (NGS) in the Setting of Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Quadruplet Induction.
Biology of Blood and Marrow Transplantation·2020· 3 citedOpen Access
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Blood·2019· 77 cited

Frequent Co-authors

Luciano J. Costa(13), Eva Medvedova(12), Rebecca Silbermann(12), Natalie S. Callander(12), Saurabh Chhabra(10), Bhagirathbhai Dholaria(10), Kelly Godby(10), Susan Bal(10), Smith Giri(10), Robert F. Cornell(10), Parameswaran Hari(10), Aric C. Hall(9), Timothy M. Schmidt(8), Binod Dhakal(8), Anita D’Souza(8), James Omel(4), Gayathri Ravi(3), Binod Dhakal(2), Racquel Innis-Shelton(2), Jim Omel(2)